The Use of Biomarkers in Prostate Cancer Screening and Treatment.
- 1 January 2017
- journal article
- review article
- Published by IMR Press
- Vol. 19 (4), 221-234
- https://doi.org/10.3909/riu0772
Abstract
Prostate cancer screening and diagnosis has been guided by prostate-specific antigen levels for the past 25 years, but with the most recent US Preventive Services Task Force screening recommendations, as well as concerns regarding overdiagnosis and overtreatment, a new wave of prostate cancer biomarkers has recently emerged. These assays allow the testing of urine, serum, or prostate tissue for molecular signs of prostate cancer, and provide information regarding both diagnosis and prognosis. In this review, we discuss 12 commercially available biomarker assays approved for the diagnosis and treatment of prostate cancer. The results of clinical validation studies and clinical decision-making studies are presented. This information is designed to assist urologists in making clinical decisions with respect to ordering and interpreting these tests for different patients. There are numerous fluid and biopsy-based genomic tests available for prostate cancer patients that provide the physician and patient with different information about risk of future disease and treatment outcomes. It is important that providers be able to recommend the appropriate test for each individual patient; this decision is based on tissue availability and prognostic information desired. Future studies will continue to emphasize the important role of genomic biomarkers in making individualized treatment decisions for prostate cancer patients.This publication has 100 references indexed in Scilit:
- Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancerProstate Cancer and Prostatic Diseases, 2013
- Urine TMPRSS2:ERG Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSAScience Translational Medicine, 2011
- A Multicenter Study of [-2]Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen RangeJournal of Urology, 2011
- Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective studyThe Lancet Oncology, 2011
- Integrative Genomic Profiling of Human Prostate CancerCancer Cell, 2010
- Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate‐specific antigenCancer, 2010
- Mortality Results from a Randomized Prostate-Cancer Screening TrialThe New England Journal of Medicine, 2009
- Screening and Prostate-Cancer Mortality in a Randomized European StudyThe New England Journal of Medicine, 2009
- Lead Time and Overdiagnosis in Prostate-Specific Antigen Screening: Importance of Methods and ContextJNCI Journal of the National Cancer Institute, 2009
- FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcomeBritish Journal of Cancer, 2007